Company Valuation. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment. The Company's valuation estimates for purposes of this Offering have been arrived at by management using a risk adjusted NPV (Net Present Value) assessment of projected future cash flows which the Company believes are based on reasonable assumptions and published EBITDA multiples in the Medical Device industry as set forth below. There has not been a third party validation on the Company's actual or projected valuation. Therefore, the price per share may not represent the fair market value of the Securities being offered.



Description of the Business

Please refer to Exhibit F for relevant references

QuadVantage Technology, Inc., incorporated in Delaware on October 2, 2018, develops surgical solutions, procedures, instruments and implants that make ACL reconstruction surgery easier to perform and deliver better results in cases where a Quadriceps graft is used as the replacement tendon. The Company's Quadriceps Autograft System equips surgeons with technology that provides a reliable surgical solution that enables a less painful, stronger, less likely to fail, cosmetically superior ACL reconstruction procedure for patients at any age.

The QuadVantage Quadriceps Autograft System makes harvesting of the Quadriceps tendon, which is believed to be superior to other traditional alternatives, possible without adding complexity, requiring increased skill or adding significant cost. The instrumentation the Company provides, coupled with its patented procedures, improves results, minimizes the trauma associated with ACL reconstruction surgery, lowers surgical complexity, reduces the need for narcotics to ease pain and shortens recovery times – a New Gold Standard.

ACL Injuries and Problems with Mainstream Reconstruction Methods

An ACL injury is a tear or sprain of the anterior cruciate ligament (ACL). The ACL ligament is one of the major ligaments in your knee. As society, at all ages, moves to more active lifestyles and participation in sports increases, the incidence of ACL injuries - and the need for better repair solutions - continues to climb. According to data from Transparency Market Research 2021, over 900,000 ACL reconstruction surgeries are expected to be performed in North America and Europe in 2023.

Mainstream ACL reconstruction techniques use Patellar, Hamstring or Allograft (cadaver) tendon grafts as replacements for the ruptured ACL tendon. In some cases, a bone fragment ("plug") is carved out of the kneecap and remains attached to one end of the soft tissue graft that is to be used as the replacement tendon.



While Patellar and Hamstring tendon grafts currently represent the majority of the ACL reconstruction "market", key issues continue to plague patients that undergo these surgeries.

The most common issues relate to short and long term pain, the use of narcotics to manage pain, graft strength/ risk of failure, length of rehabilitation and aesthetics (scarring).

Published studies continue to show that the Quadriceps tendon provides significant advantages to patellar, hamstring and cadaver tendons currently used in ACL reconstruction. The Quadriceps tendon has higher tensile strength and has been shown to have a lower risk of failure. In addition, the Quadriceps tendon regenerates over time.

The Company believes that the surgical complexity associated with harvesting the Quadriceps tendon has prevented it from becoming a widely performed procedure in spite of its obvious benefits. Use of the Quadriceps tendon in ACL reconstruction surgery has generally remained the purview of high end specialists who perform the procedure by hand. However, as the evidence grows, the Company believes, based on feedback it has received from surgeons, that the market is predisposed to adopt the quad tendon solution – QuadVantage addresses the complexity issue by providing surgeons with a reliable method and set of instrumentation that limits the amount of guesswork and manually guided (specialist) steps the surgeon has to take.

The QuadVantage Solution

The QuadVantage solution includes a minimally invasive procedure, protected by patents granted in the U.S., and a set of patented (refer to Intellectual Property section of this Form C) re-usable and recyclable instruments that facilitate harvesting a Quadriceps tendon graft, with or without a patellar bone segment ("bone plug"). The reusable instruments are intended for multiple years of use and currently include:

1. A Set of EZ Bone Saw Guides: Used to ensure an accurately measured, consistently shaped bone plug as required for each case. Devices provide measurement support for 8mm, 9mm, 10mm and 11mm bone plugs and take the guesswork out of positioning, sizing, shaping and harvesting a bone plug from the knee cap. Typically, sizing and shaping of the bone plug is done without the benefit of a guide – which can lead to too small, too large or misshapen bone plugs. European patent pending. U.S. patent 11,376,022 was granted on July 5th, 2022.



2. A re-usable, variable width, double scalpel – the VeriBlade™: Used to initiate harvesting of the Quadriceps tendon and to pre-shape the width of the graft along its intended length. If done by hand, it is very difficult to maintain parallel edges along the full length of the graft and sections of the graft may be too narrow or too wide. This device uses standard scalpels (not shown) available in any surgery center. U.S. and European patent(s) pending.

3. A re-usable Graft Harvester: Used to carve a section of the Quadriceps tendon from the upper leg without the need for an additional incision once the bone plug has been harvested and the work to pre-shape the width of the graft has been completed. The Graft Harvesting Knife utilizes different sizes of disposable blades, provided by QuadVantage, that allow customization of the size of the graft to the patients' needs. U.S. and European patent(s) pending.



Two form factors – Adult and Tendon Only/Pediatric
Instruments are shown here without disposable Blades

4. A re-usable Graft Extractor: Used to sever the graft from the Quadriceps, at the far end (away from the kneecap/ under the skin), without the need for an additional incision. The device ensures a clean square cut that maximizes the length of the graft. U.S. and European patent(s) pending.

The Company will sell proprietary disposable and recyclable surgical blades that mate with the re-usable instruments. Disposable blades will be specialized by size and application (Pediatric, Tendon Only and procedures where a bone plug is taken). U.S. and European patent(s) pending. (not all Blades shown)



We believe that there are currently no other competitors in the market that provide the type of comprehensive solution for harvesting of the Quadriceps tendon for ACL reconstruction that QuadVantage will offer. In addition, the Company expects that the cost per case of its full Quadriceps surgical solution will be the lowest in the industry.

We are also developing a fixation device (used to secure the graft into position inside the knee joint) that we expect will further differentiate the Company's ACL reconstruction product line. The Company expects the new fixation device to provide significant advantages over devices currently on the market that are used in applications where traditional bone plug / screw solutions do not work. The fixation product line is in the early stages of development and testing and is not expected to be available to market until late 2024 (assuming development and testing proceed on target). In order to protect the Company's competitive advantage while this fixation device's patent protection is pending, details provided herein are limited for competitive reasons.

Intellectual Property

Our product(s) and surgical methods have been proven in over 100 clinical cases performed under the supervision of our founder, Dr. Burroughs, and his team. The results have been excellent. Our fourth generation of products, enhanced at each stage to incorporate learnings from actual cases and feedback from unaffiliated surgeons, are now in sample production – we expect to receive our first shipment of fourth generation product in July. A strong intellectual property portfolio has been built. The patents, which cover both the design and utility of the instruments include method patents that, we believe, will make copying difficult. The list below provides an overview of the Company's core intellectual property:

Official Number	Marketing Name	Status	Notes
112023028474-9-BR 342973-MX	V-Blade Harvestor	2 Granted Brazil, Mexico	Subject to Quadvantage LLC license
9107700-US	Harvesting Procedure	Granted US	Subject to Quadvantage LLC license
8,894,675 - US	Graft Extractor	Granted US	Subject to Quadvantage LLC license
8,894,676 - US	Graft Extractor	Granted US	Subject to Quadvantage LLC license
9,044,260 -US	Extractor Procedure	Granted US	Subject to Quadvantage LLC license
16/515,859; PCT/US200/042482; EP20753578.2	EZ Bone Cutting Guide	Pending Europe, Granted US	Not subject to licensing
17/323,736; PCTUS2022/072118	T-Blade Cutter Disposable Blade(s)	Pending US/Europe	Not subject to licensing
17/486,257	VeriBlade	Pending US/Europe	Not subject to licensing
63/364,202	Fixation Anchor	Filed	Not subject to licensing

Note: QuadVantage Technology, Inc. (the Company) is not the same entity as Quadvantage, LLC (the Licensor). Quadvantage, LLC licenses certain intellectual property to QuadVantage Technology, Inc. pursuant to the License Agreement.

Please see page 40 for a discussion of the Quadvantage, LLC License.

In addition to the material patents listed above, we have secured the following trademarks:

Country	Application #	Title	Date Registered
United States	88334214	Quadvantage	Pending
Canada	1,994,439	Quadvantage	Pending
Europe	1,496,265	Quadvantage	4/15/2020
United States	88483279	Quadvantage Stylized (logo)	Pending
Canada	1,111,386	Quadvantage Stylized (logo)	10/13/2021
Europe	1,515,139	Quadvantage Stylized (logo)	8/20/2020
United States	88563705	VeriBlade	Pending

Government Regulation

QuadVantage instruments are classified as Class 1 Medical Devices. As shown in the table below, we are required to register our products with the FDA and must meet the FDA's quality and manufacturing requirements. Our products are not subject to pre-market notification or FDA pre-approval prior to launch. Post launch, the Company is subject to on-going FDA audits to ensure compliance with the quality, testing and manufacturing requirements imposed by the agency.

Class-1	Class-2	Class-3
No FDA pre- approval needed Must register device & company on FDA website. Must complete safety testing as prescribed by the FDA and have an adequate Quality system in place. Subject to on-going FDA audits post launch.	**FDA clearance required.** Typically via 510 (K) Premarket notification submission. Subject to on-going FDA audits post launch.	**FDA approval required.** Typically via Premarket (PMA) approval process. Subject to on-going FDA audits post launch.

The FDA requires device testing to be in place (on a self-policing basis / subject to FDA audit) to ensure manufacturing processes and materials do not cause irritation or sensitization issues. Since our instruments are 100% surgical grade stainless steel (passivated in manufacturing), we believe they do not require additional bio-compatibility testing. We do, however, have to justify forgoing the biocompatibility testing prior to commercially launching our products. We feel confident that we will be able to justify our position and will seek sign-off from a qualified regulatory agent before launching our products. Refer to "Use of International Standard ISO10993-1, Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management Process" for additional information.

The FDA requires, pre-product launch, that the manufacturer prove that packaging and sterilization procedures and materials are effective in ensuring and maintaining effective sterilization. The Company expects to meet this requirement by conducting active third party testing of the final product and packaging. We have not yet finalized our packaging design or begun testing to ensure we are in compliance with the FDA's packaging and sterilization requirements. We believe that final packaging design and sterilization testing is a 4 to 6 month effort but are not in a position to initiate this activity until adequate funding has been secured.

The Company believes no further FDA clinical trials or pre-approval submissions are required. Remaining pre-launch activities relate to manufacturing preparedness, sterilization process development and packaging design as required by the FDA. We believe all remaining pre-launch activities are low risk to complete. Once we secure adequate funding, it should take us about 6 months to begin commercialization of our products and surgical solution.

Business Milestones and Commercialization Strategy

The Company's business development timeline and plans are as depicted below:



This timeline is keyed off of the point at which we are able to secure sufficient funds to proceed with the business development actions noted above in the "post funding" column. Any significant delays in raising funds beyond the end of 2022 could cause a non-linear delay in achievement of all of our projections and milestones, loss of key suppliers and a loss of market opportunity.

The Company expects that it will take at least $3 Million in total funding by the end of 2023 to adequately support it through to profitable performance post launch.

The Company plans to focus on the U.S. market and will seek to develop licensees / distribution partners in Europe and Latin America. The Company's financial projections do not include income from licensing products into the European or Latin American markets – this has been left as an upside to mitigate risk.

The Company expects to employ a U.S. based supply chain for all of its products.

In the U.S., QuadVantage will employ a direct key account sales model that will target the highest volume surgery centers and key thought leaders, bypass third party distribution and provide additional savings / discounts to its direct customers.

The Company does not believe that it needs to build an extensive sales team to execute this strategy as the customer base is highly concentrated in its U.S. target market and the procedure is easy to learn

Competition

The primary "competitive challenge / opportunity" will be to convince orthopedic surgeons to move away from Patellar, Hamstring and expensive Allograft (cadaver) reconstruction techniques and adopt Quadriceps grafts as the replacement tendon of choice. We will have significant help in this quest as the evidence builds regarding the advantages of Quadriceps ACL reconstruction. We do not expect to convince the few highly specialized surgeons that work with professional athletes, where cost is no object, to use our technique although some will see value in the instruments themselves.

Our most important task will be to convince mainstream surgeons that using our technique and instruments provides them with the best and most complete solution: a solution that is easy to use, low cost, reliable and delivers better outcomes for their patients at any age. This is where the Company will focus its energy. Product competition is limited as only a handful of companies offer direct or partial alternatives to the solution QuadVantage is bringing to market.

In the U.S., one of the top players in the industry markets a disposable product that aids in the harvest and extraction of a tendon only (no bone plug) Quadriceps graft. QuadVantage, we believe, supports tendon only procedures with a more complete solution and, based on recent clinical findings and industry rhetoric, we believe the market will move away from tendon only transplants as the evidence points to a better result when a bone plug is employed. This competitor has begun to bring attention to the space and earn revenue; they have considerable resources to develop products and services. It will be critical for QuadVantage to enter the U.S. market and establish its position as early as possible.

The Company believes that its Intellectual Property, as it relates to the inclusion of a bone plug in combination with a Quadriceps graft, will make it difficult for others to truly offer a complete competitive solution.

In Europe, there is one mid-level player that the Company would consider a direct competitor. It provides a re-usable instrument and disposable blade solution somewhat similar to the QuadVantage Quadriceps Autograft System. It does not have a significant presence in the U.S. market and its products appear to be more expensive and difficult to use. It has established a small position in the European market.

The Company is aware of one major competitor that has been rumored for some time to be working on a solution for Quadriceps reconstruction surgery. It is likely that this competitor will enter the market in late 2022 or early 2023. The scope and nature of their solution is unknown. How this competitor navigates around the QuadVantage patents, particularly in the US, remains to be seen.

QuadVantage expects to be the low-cost provider on a per case cost basis. While the Company's intellectual property portfolio provides some protection, there is no guarantee that current or new competition won't effectively find a way around our patents or improve the cost and performance of their products. In addition, we may lack resources to institute adequate remedies against others who may infringe on our intellectual property. Researchers have also been working for decades to develop artificial tendon materials that could be used in ACL reconstruction surgery. When such an artificial solution will be available and how effective it will be is unknown.

Given the above, while also considering the risk factors noted in this Form C, the Company believes that it is in a good position to acquire market share, particularly in the U.S., if it enters the market quickly.

USE OF PROCEEDS

The following table illustrates how we intend to use the net proceeds received from this Offering. The values below are not inclusive of payments to financial and legal service providers and escrow related fees, all of which were incurred in the preparation of this Offering and are due in advance of the closing of the Offering.

Use of Proceeds USD	Target Amount Raised $25,000	% of Proceeds	$1,000,000 Raised	% of Proceeds	$3,000,000 Raised	% of Proceeds	Maximum Offering Amount Raised $5,000,000	% of Proceeds if Maximum Offering Amount Raised
Intermediary Fees	$ 750	3.0%	$ 30,000	3.0%	$ 90,000	3.0%	$ 150,000	3.0%
R&D & Testing	$ 5,750	23.0%	$ 480,000	48.0%	$ 710,000	23.7%	$ 750,000	15.0%
Inventory		0.0%	$ 200,000	20.0%	$ 300,000	10.0%	$ 850,000	17.0%
Sales & Marketing	$ 14,000	56.0%	$ 155,000	15.5%	$ 635,000	21.2%	$ 1,075,000	21.5%
Legal & Regulatory	$ -	0.0%	$ 30,000	3.0%	$ 150,000	5.0%	$ 225,000	4.5%
Team Compensation	$ -	0.0%	$ 65,000	6.5%	$ 870,000	29.0%	$ 1,545,000	30.9%
G&A/ Other	$ 4,500	18.0%	$ 40,000	4.0%	$ 245,000	8.2%	$ 405,000	8.1%
Total	**$ 25,000**	**100.0%**	**$ 1,000,000**	**100.0%**	**$ 3,000,000**	**100.0%**	**$ 5,000,000**	**100.0%**

R&D and Testing: The Company currently outsources the majority of its R&D and testing work to Robling Medical, Inc. Robling provides product development, design for manufacturability and design validation support to the Company. These costs are included in this category. In addition, this category also includes the cost of sterilization and packaging testing mandated by the FDA and planned clinical testing of products under development. The Company intends to bring the majority of these activities in-house and limit the use of external resources starting in 2023. This transition is reflected in the use of funds shown above.

Inventory: Investment in period end inventory to support future sales.

Sales and Marketing: Investment in advertising and collateral materials to support sales, market research, marketing to support fundraising paid to third parties, and contract sales resources. The Company expects to transition away from contract sales resources and build its own business development and sales team starting in 2023.

Legal Expenses: The costs of maintaining and filing patents, regulatory consulting support for FDA and SEC related matters and ordinary legal support required by the Company in the conduct of its business.

Team Compensation: Payroll costs for the CEO, CFO, Chief Medical Officer, Finance Team, Sales and Marketing Team and Research and Development Team.

The team currently consists of two (2) employees, the CEO/CFO, and the Chief Accounting Officer. The current team will defer cash compensation such that no funds from the first $500,000 raised will be used to fund payroll. Refer to "Transactions with Related Persons, Conflicts of Interest and Other Material Transactions and Disclosures", starting on page 39, for additional details on compensation for executive officers of the Company.

Once adequate funds have been raised the Company will start to build an internal R&D team, an accounting/finance team to support the Chief Accounting Officer, and a business development and sales team. Given the Company's virtual business model it expects that employment by 2025 will max out at approximately 20 full time team members.

G&A / Other: Covers third party audit costs, Advisory Board remuneration, servicing of credit card debt, liability insurance and the payment of expenses funded by the current team which the Company has pledged to repay. Refer to "Transactions with Related Persons, Conflicts of Interest and Other Material Transactions and Disclosures" starting on page 39 of this Form C for additional details on the nature and timing of repayments to the team.

DIRECTORS, OFFICERS AND MANAGERS

The directors, officers and managers of the Company are listed below along with all positions and offices held at the Company and their principal occupation and employment responsibilities for the past three (3) years.

Name	Positions and Offices Held at the Company	Principal Occupation and Employment Responsibilities for the Last Three (3) Years	Education
Thomas Gutierrez	President, CEO, CFO and Director	CEO of QuadVantage Technology, Inc. since 2018, Owner and Operator of Obsidian Technology, LLC	BSEE Florida Institute of Technology
Paul L. Burroughs	Chairman of the Board, Founder, non-employee Chief Medical Officer ("CMO")	Orthopedic Surgeon, MD and Lead Partner at The Bone & Joint Surgery Clinic in Raleigh, NC for the last 20 years	BS Biology UNC-CH, MD UNC-CH
Janet Gutierrez	Chief Accounting Officer	Chief Accounting Officer for QuadVantage Technology, Inc. since the Company's formation in 2018	BSBA and MBA from The Ohio State University

Thomas Gutierrez:

40 years of CEO, President, COO and General Management level responsibility leading the development and operation of highly technical public, private and private equity-controlled companies serving the capital equipment, advanced materials, consumables, electronic component, medical and service industries. Entities ranged in size from pre-revenue to $3 Billion in annual revenue. Extensive M&A, IPO and world-wide R&D, Manufacturing, Marketing, Financial and Operations experience. Former CEO of Invensys plc Power Systems, BTR plc Sensors, Xerium Technologies (NYSE), GT Advanced Technologies (NASDAQ), Oliventures, Inc., and President of various Pitney Bowes businesses. Early career as an R&D and manufacturing engineer and manufacturing manager at Harris Semiconductor, Magnavox, Digital Equipment Corporation, Motorola and NCR. In addition to current responsibilities as CEO/CFO of QuadVantage, Mr. Gutierrez runs a consulting business, Obsidian Technology, LLC, of which he is the sole owner.

Paul L. Burroughs, III, MD:

Dr. Paul L. Burroughs, III, a graduate of the University of North Carolina Medical School, has over 20 years of experience as a physician in Orthopedic Surgery and Sports Medicine. He specializes in arthroscopy of the knee and shoulder, advanced joint replacement techniques, knee replacements utilizing Exparel pain management and sports medicine. He also performs partial knee replacements, ACL ligament reconstruction, rotator cuff repairs, reconstruction of shoulder dislocations, and ultrasound guided injections. Dr. Burroughs is certified by the American Board of Orthopedic Surgeons and is published in the American Journal of Sports Medicine and the Journal of Arthroplasty. Dr. Burroughs serves as the Company's non-employee CMO.

Janet Gutierrez:

Ms. Gutierrez has a BSBA (Business and Accounting) and MBA from The Ohio State University and has over 20 years of senior level experience in finance. She served as an Auditor/CPA at Ernst and Whinney (predecessor to E&Y), as Controller at Berwick Steel, Scientific Columbus and Daytronic Corporation and as group Controller at various Invensys plc businesses. Ms. Gutierrez is retired and has served as CFO of various Gutierrez family businesses and as QuadVantage's Chief Accounting Officer.